Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22010838 | 0.87 | RARB (0.35) | SPHK1 | |
| SCHEMBL22011219 | 0.86 | SPHK1 (0.46) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL22011811 | 0.85 | CYP3A4 (0.32) | CYP2C9MAPTGAACYP3A4CYP2C8 | |
| SCHEMBL22010986 | 0.85 | MAPT (0.33) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL22010997 | 0.85 | MAPT (0.33) | MAPTMEN1KMT2AGAA | |
| SCHEMBL22011221 | 0.80 | SPHK1 (0.34) | MAPTSPHK1 | |
| SCHEMBL22011215 | 0.79 | CYP2C9 (0.36) | CYP2C9MAPTALDH1A1LMNAMEN1 | |
| SCHEMBL22010813 | 0.79 | MAPT (0.32) | MAPTMEN1KMT2AGAA | |
| SCHEMBL22010971 | 0.79 | — | — | |
| SCHEMBL22011232 | 0.78 | MAPT (0.32) | MAPTMEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | JNC CORPORATION (JP) | 2020-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10662378-B2 | Compound having fluorodibenzofuran ring, liquid crystal composition and liquid crystal display device | YBX1, ZKSCAN2, RCC1 | CYP2C9 1213/4885MAPT 1234/4885ALDH1A1 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.